Maven Securities’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Maven Securities’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,000	Closed	-$900K	–	1177
2022 Q3	$900K	Buy	+4,000	New	+$810K	0.02%	579
2022 Q1	–	Sell	-4,073	Closed	-$534K	–	1151
2021 Q4	$534K	Buy	+4,073	New	+$526K	0.02%	536
2021 Q3	–	Sell	-50,000	Closed	-$5.72M	–	1328
2021 Q2	$5.72M	Hold	50,000	–	–	0.23%	73
2021 Q1	$5.84M	Sell	50,000 -25,000	-33%	-$2.83M	0.26%	70
2020 Q4	$7.77M	Buy	+75,000	New	+$6.95M	0.77%	29
2020 Q1	–	Sell	-35,000	Closed	-$2.53M	–	464
2019 Q4	$2.53M	Buy	35,000 +21,920	+168%	+$960K	0.23%	80
2019 Q3	$213K	Sell	13,080 -11,920	-48%	-$232K	0.07%	177
2019 Q2	$501K	Buy	+25,000	New	+$501K	0.33%	58

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Maven Securities's KRTX Position: Q4 2022 in Review

Maven Securities sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 4,000 shares — an estimated $900K sold.

Maven Securities first reported a position in KRTX in Q2 2019 and held it in 8 quarters. The position peaked at $7.77M in Q4 2020. 248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

Maven Securities reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Maven Securities sold 4,000 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $900K.
Maven Securities first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
Maven Securities's Karuna Therapeutics, Inc. Common Stock position peaked at $7.77M in Q4 2020.
248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Maven Securities's 13F filing for Q4 2022, filed 14 Feb 2023.